A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.
Medical Device Network on MSN13d
Foresight announces trial launch for cHL treatment with ctDNA-based MRD testForesight Diagnostics has launched the PRECISE-HL trial, which will use the Foresight Clarity LDT to treat patients with ...
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
The trial will also explore end of therapy ctDNA-MRD analysis as an exploratory endpoint. According to the company, the standard treatment for newly diagnosed advanced cHL patients currently ...
Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.
while patients with detectable ctDNA will continue with the full six cycles of nivolumab + AVD. End of therapy ctDNA-MRD analysis will also be an exploratory endpoint for the trial.
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback